Posters

      Characterization of the Vitrocell 24/48 in vitro exposure system using mainstream cigarette smoke

      Frentzel, S.; Majeed, S.; Kuehn, D.; Leroy, P.; Guy, P.; Knorr, A.; Kuczaj, A. K.; Nordlund, M.; Hoeng, J.; Peitsch, M. C.
      Conference date
      Mar 23, 2015
      Conference name
      Society of Toxicology (SOT) 2015
      Link to more information
      Topic
      Summary

      Introduction: Our current knowledge about the effect of cigarette smoke (CS) in vitro is largely based on exposing cells growing in submersed conditions to CS fractions. Although the particulate and gas–vapor phases (or CS condensate) are still widely used for in vitro studies, they have some important limitations. In particular, the method used for trapping them might alter the chemical composition of each fraction. Some compounds (especially volatile compounds) cannot be trapped quantitatively; the filters or other components of the collection system might leach impurities into the collected material and the solvents used might react with constituents of the smoke fraction. Most importantly, analysis of the individual fractions might underestimate the overall risk attributable to CS through combined exposure to multiple toxicants. In addition, using submersed cell culture systems to test the effect of CS fractions, do not resemble the conditions under which cells are exposed to CS in the human lung. For these reasons, researchers are increasingly using culture systems where cells are exposed to CS at the air-liquid interface (ALI). Only a few exposure systems are presently available that enable CS exposure of living cells at the air–liquid interface, of which one of the most versatile is the Vitrocell® system (Vitrocell® Systems GmbH). To assess its performance and optimize the exposure conditions, we characterized a Vitrocell® 24/48 system connected to a 30-port carousel smoking machine.  

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.